818 related articles for article (PubMed ID: 25739118)
1. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
2. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
[TBL] [Abstract][Full Text] [Related]
3. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.
Wang W; Qin JJ; Voruganti S; Wang MH; Sharma H; Patil S; Zhou J; Wang H; Mukhopadhyay D; Buolamwini JK; Zhang R
Gastroenterology; 2014 Oct; 147(4):893-902.e2. PubMed ID: 25016295
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Oct; 6(32):33106-19. PubMed ID: 26461225
[TBL] [Abstract][Full Text] [Related]
5. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
6. Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy.
Qin JJ; Wang W; Sarkar S; Voruganti S; Agarwal R; Zhang R
Oncotarget; 2016 May; 7(22):32566-78. PubMed ID: 27105525
[TBL] [Abstract][Full Text] [Related]
7. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
8. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
9. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
11. Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
Xiong J; Li J; Yang Q; Wang J; Su T; Zhou S
Breast Cancer Res; 2017 Mar; 19(1):27. PubMed ID: 28274247
[TBL] [Abstract][Full Text] [Related]
12. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
[TBL] [Abstract][Full Text] [Related]
13. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
Xiong J; Su T; Qu Z; Yang Q; Wang Y; Li J; Zhou S
Oncotarget; 2016 Apr; 7(17):23933-46. PubMed ID: 27004407
[TBL] [Abstract][Full Text] [Related]
14. The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells.
Raza S; Ohm JE; Dhasarathy A; Schommer J; Roche C; Hammer KD; Ghribi O
Mol Cell Biochem; 2015 Dec; 410(1-2):187-95. PubMed ID: 26350565
[TBL] [Abstract][Full Text] [Related]
15. p53-Mdm2 inhibitors: patent review (2009 - 2010).
Kamal A; Mohammed AA; Shaik TB
Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
[TBL] [Abstract][Full Text] [Related]
16. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
17. Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene.
Kong Y; Lu ZL; Wang JJ; Zhou R; Guo J; Liu J; Sun HL; Wang H; Song W; Yang J; Xu HX
Oncol Rep; 2016 Sep; 36(3):1447-56. PubMed ID: 27432230
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.
Azmi AS; Philip PA; Aboukameel A; Wang Z; Banerjee S; Zafar SF; Goustin AS; Almhanna K; Yang D; Sarkar FH; Mohammad RM
Curr Cancer Drug Targets; 2010 May; 10(3):319-31. PubMed ID: 20370686
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule inhibitors of the p53-MDM2 interaction.
Vu BT; Vassilev L
Curr Top Microbiol Immunol; 2011; 348():151-72. PubMed ID: 21046355
[TBL] [Abstract][Full Text] [Related]
20. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
